IBDEI0YM ; ; 01-FEB-2022
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 01, 2022
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,15633,1,4,0)
 ;;=4^E11.319
 ;;^UTILITY(U,$J,358.3,15633,2)
 ;;=^5002633
 ;;^UTILITY(U,$J,358.3,15634,0)
 ;;=G40.909^^61^760^76
 ;;^UTILITY(U,$J,358.3,15634,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,15634,1,3,0)
 ;;=3^Seizure Disorder NOS
 ;;^UTILITY(U,$J,358.3,15634,1,4,0)
 ;;=4^G40.909
 ;;^UTILITY(U,$J,358.3,15634,2)
 ;;=^5003865
 ;;^UTILITY(U,$J,358.3,15635,0)
 ;;=N52.9^^61^760^30
 ;;^UTILITY(U,$J,358.3,15635,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,15635,1,3,0)
 ;;=3^Erectile Dysfuntion,Unspec
 ;;^UTILITY(U,$J,358.3,15635,1,4,0)
 ;;=4^N52.9
 ;;^UTILITY(U,$J,358.3,15635,2)
 ;;=^5015763
 ;;^UTILITY(U,$J,358.3,15636,0)
 ;;=I50.22^^61^760^39
 ;;^UTILITY(U,$J,358.3,15636,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,15636,1,3,0)
 ;;=3^Heart Failure,Systolic,Chronic
 ;;^UTILITY(U,$J,358.3,15636,1,4,0)
 ;;=4^I50.22
 ;;^UTILITY(U,$J,358.3,15636,2)
 ;;=^5007241
 ;;^UTILITY(U,$J,358.3,15637,0)
 ;;=I50.32^^61^760^37
 ;;^UTILITY(U,$J,358.3,15637,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,15637,1,3,0)
 ;;=3^Heart Failure,Diastolic,Chronic
 ;;^UTILITY(U,$J,358.3,15637,1,4,0)
 ;;=4^I50.32
 ;;^UTILITY(U,$J,358.3,15637,2)
 ;;=^5007245
 ;;^UTILITY(U,$J,358.3,15638,0)
 ;;=I50.42^^61^760^38
 ;;^UTILITY(U,$J,358.3,15638,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,15638,1,3,0)
 ;;=3^Heart Failure,Systolic & Diastolic,Chronic
 ;;^UTILITY(U,$J,358.3,15638,1,4,0)
 ;;=4^I50.42
 ;;^UTILITY(U,$J,358.3,15638,2)
 ;;=^5007249
 ;;^UTILITY(U,$J,358.3,15639,0)
 ;;=I13.0^^61^760^32
 ;;^UTILITY(U,$J,358.3,15639,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,15639,1,3,0)
 ;;=3^HTN Hrt & CKD w/ Hrt Fail w/ Stage 1-4 Chr Kdny
 ;;^UTILITY(U,$J,358.3,15639,1,4,0)
 ;;=4^I13.0
 ;;^UTILITY(U,$J,358.3,15639,2)
 ;;=^5007067
 ;;^UTILITY(U,$J,358.3,15640,0)
 ;;=I13.2^^61^760^33
 ;;^UTILITY(U,$J,358.3,15640,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,15640,1,3,0)
 ;;=3^HTN Hrt & CKD w/ Hrt Fail w/ Stage 5 Chr Kdny
 ;;^UTILITY(U,$J,358.3,15640,1,4,0)
 ;;=4^I13.2
 ;;^UTILITY(U,$J,358.3,15640,2)
 ;;=^5007070
 ;;^UTILITY(U,$J,358.3,15641,0)
 ;;=I13.10^^61^760^34
 ;;^UTILITY(U,$J,358.3,15641,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,15641,1,3,0)
 ;;=3^HTN Hrt & CKD w/o Hrt Fail w/ Stage 1-4 Chr Kdny
 ;;^UTILITY(U,$J,358.3,15641,1,4,0)
 ;;=4^I13.10
 ;;^UTILITY(U,$J,358.3,15641,2)
 ;;=^5007068
 ;;^UTILITY(U,$J,358.3,15642,0)
 ;;=I13.11^^61^760^35
 ;;^UTILITY(U,$J,358.3,15642,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,15642,1,3,0)
 ;;=3^HTN Hrt & CKD w/o Hrt Fail w/ Stage 5 Chr Kdny
 ;;^UTILITY(U,$J,358.3,15642,1,4,0)
 ;;=4^I13.11
 ;;^UTILITY(U,$J,358.3,15642,2)
 ;;=^5007069
 ;;^UTILITY(U,$J,358.3,15643,0)
 ;;=E03.9^^61^760^45
 ;;^UTILITY(U,$J,358.3,15643,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,15643,1,3,0)
 ;;=3^Hypothyroidism,Unspec
 ;;^UTILITY(U,$J,358.3,15643,1,4,0)
 ;;=4^E03.9
 ;;^UTILITY(U,$J,358.3,15643,2)
 ;;=^5002476
 ;;^UTILITY(U,$J,358.3,15644,0)
 ;;=C61.^^61^760^49
 ;;^UTILITY(U,$J,358.3,15644,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,15644,1,3,0)
 ;;=3^Malig Neopl Prostate
 ;;^UTILITY(U,$J,358.3,15644,1,4,0)
 ;;=4^C61.
 ;;^UTILITY(U,$J,358.3,15644,2)
 ;;=^267239
 ;;^UTILITY(U,$J,358.3,15645,0)
 ;;=F11.20^^61^760^55
 ;;^UTILITY(U,$J,358.3,15645,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,15645,1,3,0)
 ;;=3^Opioid Dependence,Uncomplicated
 ;;^UTILITY(U,$J,358.3,15645,1,4,0)
 ;;=4^F11.20
 ;;^UTILITY(U,$J,358.3,15645,2)
 ;;=^5003127
